Alexis Lee

Ms. Alexis Lee

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
BBBabak Baravarian
Babak Baravarian
GKGi Kwon
Gi Kwon
JSJohn Shou
John Shou
NLNaomi Lambert
Naomi Lambert
ALAlexis Lee
Alexis Lee
TBTyler Barrett
Tyler Barrett
Introduction: Posterior tibial tendon dysfunction (PTTD) is a progressive degenerative tendinopathy often unresponsive to conservative care, necessitating surgical interventions with significant postoperative risks. Wharton’s jelly (WJ) tissue allograft from the human umbilical cord, with its collagen-rich matrix homologous to tendon tissue, presents a potential alternative intervention. This study aims to report preliminary findings on the safety and efficacy of WJ allografts for the supplementation of degenerated tissue in patients with PTTD. Material and Methods: Twenty-six patients from the observational repository were identified with PTTD (Stages II-IV) and failed at least three months of conservative care. Patients received one or two ultrasound-guided percutaneous applications of the WJ allograft. Outcomes were tracked using the Numeric Pain Rating Scale (NPRS), the Western Ontario and McMaster University Arthritis Index (WOMAC), and the Quality-of-Life Scale (QOLS) at the initial, 30, 90, and 120-day follow-ups. Results: The cohort was 62% male (n = 16) and 38% female (n = 10), with a mean age predominantly in the 70–89 range. From the initial to final visit (90 days for single applications, 120 days for double applications), the single-application group (n = 22) showed a 48.32% improvement in NPRS and a 22.73% improvement in total WOMAC. The double-application group (n = 8) showed a 50% improvement in NPRS and a 27.86% improvement in total WOMAC. A statistically significant improvement in NPRS was observed in the single-application group (p = 0.042). No adverse events were reported. Discussion: This study provides preliminary evidence that WJ tissue allografts may be a safe and effective minimally invasive application for degeneration of the PTT, which is associated with improvements in pain, function, and quality of life. Key limitations include a lack of a control group and a small cohort size. Conclusions: The positive findings of this study warrant further research through randomized controlled trials to confirm efficacy, establish optimal dosage, and compare WJ to other conservative interventions.

30 July 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
BBBabak Baravarian
Babak Baravarian
GKGi Kwon
Gi Kwon
JSJohn Shou
John Shou
NLNaomi Lambert
Naomi Lambert
ALAlexis Lee
Alexis Lee
TBTyler Barrett
Tyler Barrett
Introduction: Posterior tibial tendon dysfunction (PTTD) is a specific form of enthesopathy characterized by progressive degeneration and dysfunction of the posterior tibial tendon, often presenting with inflammation, tendon thickening, and pain along the foot. Current standard-of-care procedures produce many risks and complications, especially in operative care, highlighting the need for a favorable alternative medicine. Wharton’s jelly (WJ) possesses a collagen-rich matrix similar to tendons that can supplement tendon defects. This study aims to report supportive preliminary findings from patient-reported scales after WJ applications to patients with PTTD refractory to standard care. Materials and Methods: Twenty-six patients from the observational repository were identified with posterior tibial tendon defects who failed three months of conservative care. Patients received either a single application or two sequential applications based on the severity of their condition. The patient-reported results utilized the Numeric Pain Rating Scale (NPRS), the Western Ontario and McMaster University Arthritis Index (WOMAC), and the Quality of Life Scale (QOLS). WJ tissue allografts were applied to the structural defects in the posterior tibial tendon. No adverse events were reported. Results: Patients were categorized according to the number of applications they received. The percent improvement of each category was calculated from their initial visit to their final visit. Each dosage category observed improvement. Discussion: This study confirms that the application of WJ tissue allografts in treatment-resistant PTTD is beneficial, safe, and minimally invasive, providing preliminary evidence for utilizing WJ as an alternative method to current standard practices. Several limitations in this study included the lack of direct comparison groups with other conventional interventions and recall bias. Conclusion: The positive findings of this study indicate the need for further research to establish the best dosage protocols for Wharton’s jelly in patients suffering from PTTD.

30 July 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
BBBabak Baravarian
Babak Baravarian
GKGi Kwon
Gi Kwon
CTConrad Tamea
Conrad Tamea
JSJohn Shou
John Shou
NLNaomi Lambert
Naomi Lambert
TBTyler Barrett
Tyler Barrett
Introduction: Plantar fasciitis (PF) or plantar fasciopathy is the most common cause of heel pain in adults. 10% of the general population is affected by some severity of plantar fasciopathy. Current standard-of-care methods, both conservative and non-conservative, provide a variety of complications and side effects. Current methods are not cost-effective, with the total annual expenditure of $284 million in PF standard care. The purpose of this observational study is to evaluate the efficacy of Wharton’s jelly (WJ) when applied to defects in the plantar fascia. Materials and Methods: A cohort of nine patients with plantar fasciopathy was identified from a large observational repository for this study. Patient improvement after one application of WJ tissue allograft was assessed over 90 days using the Numeric Pain Rating Scale (NPRS), the Western Ontario and McMaster University Arthritis Index (WOMAC), and the Quality of Life Scale (QOLS). No adverse effects were reported. Results: Average scores and percent improvement were calculated from the initial application date to the final follow-up. All patients reported improvement in all scales utilized, with the most substantial improvements noted in WOMAC scores. Discussion: Although only a small cohort was observed, the positive results align with current literature that confirms the homologous nature of WJ and other connective tissues, providing a promising option for use in structural defects around the body. Conclusion: Future research is essential to establish Wharton’s jelly as a primary conservative care method in patients suffering from plantar fasciopathy.

28 February 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
CTConrad Tamea
Conrad Tamea
JBJeff Buchalter
Jeff Buchalter
JCJason Capra
Jason Capra
TGTracie Gilliland
Tracie Gilliland
NLNaomi Lambert
Naomi Lambert
TBTyler Barrett
Tyler Barrett
Introduction: With age and injury, the infiltration of fat in the paraspinal muscles can cause degeneration, disorganizing the structural integrity of the connective tissue, causing lower back pain (LBP). Human umbilical cord tissue allografts (UCTa) have a collagen-rich matrix with various ECM components that can replace damaged connective tissue. The objective of this study is to evaluate preliminary findings on the safety and efficacy of UCTa for the supplementation of degenerated tissue in thoracic and lumbar paraspinal muscles refractory to standard conservative methods. Materials and Methods: A total of 141 patients from an observational repository were identified with paraspinal muscle degeneration. Patients received one to three applications of UCTa, outcomes were tracked using the Numeric Pain Rating Scale, the Western Ontario and McMaster University Arthritis Index, and the Quality-of-Life Scale. Results: All groups showed positive improvement in the NPRS and WOMAC scales. Multi-application groups revealed statistically significant differences in the analyses. No adverse events or complications were reported. Discussion: Limitations included a lack of a control group and the increase of recall and response bias due to using patient-reported measures. Conclusion: This pilot investigation highlights the need for continued research through randomized controlled trials to validate efficacy, establish optimal dosage protocols, and compare UCTa to other conservative interventions.

23 March 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
ALAlbert Lai
Albert Lai
JBJeff Buchalter
Jeff Buchalter
JCJason Capra
Jason Capra
HJHeather Johnson
Heather Johnson
LPLonnie Peets
Lonnie Peets
TBTyler Barrett
Tyler Barrett
Introduction: With age and injury, the infiltration of fat in the paraspinal muscles can cause degeneration, disorganizing the structural integrity of the connective tissue, causing lower back pain (LBP). Human umbilical cord tissue allografts (UCTa) have a collagen-rich matrix with various ECM components that can replace damaged connective tissue. The objective of this study is to evaluate preliminary findings on the safety and efficacy of UCTa for the supplementation of degenerated tissue in thoracic and lumbar paraspinal muscles refractory to standard conservative methods. Materials and Methods: A total of 141 patients from an observational repository were identified with paraspinal muscle degeneration. Patients received one to three applications of UCTa, outcomes were tracked using the Numeric Pain Rating Scale, the Western Ontario and McMaster University Arthritis Index, and the Quality-of-Life Scale. Results: All groups showed positive improvement in the NPRS and WOMAC scales. Multi-application groups revealed statistically significant differences in the analyses. No adverse events or complications were reported. Discussion: Limitations included a lack of a control group and the increase of recall and response bias due to using patient-reported measures. Conclusion: This pilot investigation highlights the need for continued research through randomized controlled trials to validate efficacy, establish optimal dosage protocols, and compare UCTa to other conservative interventions.

18 March 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
CTConrad Tamea
Conrad Tamea
JBJeff Buchalter
Jeff Buchalter
JCJason Capra
Jason Capra
TGTracie Gilliland
Tracie Gilliland
HJHeather Johnson
Heather Johnson
TBTyler Barrett
Tyler Barrett
Introduction: Cervical paraspinal enthesopathy is characterized by fatty infiltration and muscle degeneration; current methods only provide symptomatic relief or involve significant postoperative complications. This study provides preliminary results for the clinical potential of umbilical cord tissue allografts (UCTa) in patients with cervical paraspinal enthesopathy and degeneration refractory to standard care. Materials and Methods: The Numeric Pain Rating Scale, Western Ontario and McMaster University Arthritis Index, and Quality of Life Scale were used to measure outcomes of thirty-one patients with cervical paraspinal degeneration from an observational repository who received one to three UCT allograft applications. The Wilcoxon Signed-Rank test, Mann-Whitney U test, and Jonckheere-Terpstra test were performed for the analysis. Results: Substantial percentage improvements were observed from the patient cohort, with the triple application group reporting the highest percentage improvement. Statistically significant differences were presented in all application groups. No adverse events were reported. Discussion: This study provided preliminary findings that UCTas are a safe, minimally invasive application for cervical paraspinal defects. Notable limitations included a lack of a direct comparison group and a small sample size. Conclusion: This study highlights the need for continued research to validate the preliminary results for the safety, feasibility, and efficacy of umbilical cord tissue allografts in patients with cervical paraspinal defects.